Pfizer to Spend $470 Million in Expansion of Vaccine Research Facilities
Pfizer is planning a $470 million expansion of its vaccine research facility in Pearl River, N.Y. which played a leading role on the co-development of the company’s COVID-19 vaccine with BioNTech.
A total of 19 products were discovered and developed at the site 25 miles northwest of New York City and include antibody drug conjugates, nanoparticles and bispecific monoclonal antibodies, the company said.
The facility will continue research into the messenger RNA technology that underpins the Pfizer-BioNTech COVID-19 vaccine. The expansion at the vaccine research site will include a new building and renovations for the existing facilities, Pfizer said.